How Long Does Wegovy Take to Work?

The Short Answer: Results Start Early, Peak at ~68 Weeks

Most people on Wegovy® notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins by weeks 4–8. The landmark STEP 1 clinical trial showed an average weight loss of about 14.9% of body weight at 68 weeks — roughly 16–17 months. But that's an average over a carefully managed escalation schedule, not a straight line from week one to week 68.

Here is a realistic, evidence-based look at what happens — and when.

Understanding the Dose Escalation Schedule

Wegovy is not taken at full dose from day one. Semaglutide must be introduced gradually to minimize gastrointestinal side effects like nausea and vomiting. The standard escalation schedule is:

• Weeks 1–4: 0.25 mg once weekly (starter dose)
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

The 2.4 mg maintenance dose is where the full weight-loss effect of Wegovy is realized. At 0.25 mg, you are essentially just letting your body adjust — meaningful appetite suppression at that dose is limited. This is why patience in the early weeks is essential.

Your provider may slow the escalation if side effects are significant, or occasionally allow a faster ramp-up if you are tolerating it well. The schedule above reflects the FDA-approved standard protocol.

What to Expect Week by Week

Weeks 1–4: Adjustment Phase

At 0.25 mg, many people notice subtle changes: a slightly earlier sense of fullness, mildly reduced cravings, and occasional nausea after eating. Weight loss at this stage is usually minimal — one to two pounds at most, and sometimes none at all. This is normal. The goal at this stage is tolerance, not transformation.

Side effects are most common here: nausea, mild stomach discomfort, constipation, or burping. These usually improve as your body adjusts.

Weeks 5–12: Early Results

As the dose increases to 0.5 mg and then 1.0 mg, most people begin to feel meaningful appetite suppression. Food noise — the constant mental chatter about what to eat next — often diminishes noticeably. Portions naturally get smaller. Weight loss during this phase typically ranges from 2–5% of starting body weight, depending on diet and activity level.

Some people see faster results; others are slower. Both are consistent with clinical data. The important thing is that the trajectory is moving in the right direction.

Weeks 13–20: Accelerating Progress

At 1.7 mg and approaching 2.4 mg, appetite suppression is at or near its maximum for most patients. This is often the phase where patients report the most dramatic subjective changes — food simply isn't as compelling, and eating less feels effortless rather than forced. Average weight loss by week 20 in clinical trials was approximately 9–10% of body weight.

Weeks 20–68: Maintenance and Continued Loss

At the full 2.4 mg dose, weight loss continues — though the rate often slows as you approach a new set point. Clinical trials show that weight loss continues through approximately 52–68 weeks before plateauing. The STEP 1 trial average of ~15% body weight loss was measured at week 68, with some patients losing 20% or more.

It's important to understand that Wegovy works best as part of a comprehensive lifestyle approach. Patients who also improve their diet and increase physical activity consistently achieve better outcomes than those relying on medication alone.

Realistic Results: What Clinical Trials Actually Show

The STEP clinical trial program — the pivotal series of trials for Wegovy — provides the most reliable benchmarks:

• STEP 1: Adults with obesity, no diabetes → average 14.9% body weight loss at 68 weeks
• STEP 2: Adults with obesity and type 2 diabetes → average 9.6% body weight loss at 68 weeks (diabetes affects response)
• STEP 3: Intensive behavioral therapy added → average 16% body weight loss
• STEP 4: Patients who switched from semaglutide to placebo regained weight; those who stayed on semaglutide maintained loss

These numbers represent medians and averages. Individual results vary based on starting weight, adherence, diet quality, physical activity, genetics, and metabolic health. Some people are "high responders" who lose significantly more; others respond more modestly.

What if Wegovy Doesn't Seem to Be Working?

If you're past week 16 (full maintenance dose) and haven't lost at least 5% of your body weight, that's a signal worth discussing with your provider. Non-response to semaglutide does occur and may indicate that a different medication or approach could be more effective.

Options your provider might discuss include switching to tirzepatide (the active ingredient in Zepbound®), which targets both GLP-1 and GIP receptors and shows somewhat stronger average weight loss in head-to-head data, or evaluating other factors like thyroid function, medication interactions, or sleep disorders that could be limiting your results.

Wegovy Is a Long-Term Treatment

A critical point that is often underemphasized: weight loss medications like Wegovy work for as long as you take them. The STEP 4 trial demonstrated that patients who discontinued semaglutide after 68 weeks regained most of their lost weight within a year. This isn't a failure of willpower — it reflects the chronic nature of obesity and the physiological role GLP-1 plays in weight regulation.

For most patients, long-term or indefinite use is the expectation, similar to how someone with high blood pressure would use antihypertensive medication. Working with a provider to manage your treatment over time — rather than thinking of it as a short course — produces the best sustained outcomes.

At Truventa Medical, our licensed providers manage weight loss treatment from the initial consultation through ongoing care, with regular check-ins to adjust your plan as needed. If you're wondering whether Wegovy, compounded semaglutide, or another GLP-1 option is right for you, we can help you find out.